Exciva develops clinical-stage biopharmaceutical therapies focused on addressing neuropsychiatric symptoms associated with dementia.
Exciva has raised $59.4M in total funding. The most recent round was Series B. The last funding was announced in January 2026.
Exciva's investors include Andera Partners, EQT Life Sciences, Modi Ventures, Fountain Healthcare Partners, Carma Fund.
Exciva is headquartered in Heidelberg, Germany.
Exciva develops clinical-stage biopharmaceutical therapies focused on addressing neuropsychiatric symptoms associated with dementia.
Exciva is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Exciva — Funding & Investors." VCBacked, January 20, 2026, https://www.vcbacked.co/company/exciva. Accessed October 29, 2026.
VCBacked. (2026). Exciva — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/exciva
{{cite web |title=Exciva — Funding & Investors |url=https://www.vcbacked.co/company/exciva |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated